Saturday, April 30, 2011

Wow Depo Provera!!

Hello hope everyone is having a good day! Today's subject as you can tell is the contraception shot Depo Provera. I have included the info of warning signs for this particular method of birth control. Now it is in your hands to make that decision on whether or not you want to continue with this drug/try this drug. I personally think the risks out weight the benefits. I hope this blog is of any help to those reading. I love you all and God bless you!!

Tomorrows subject the benefit of taking the pill Yasmin.

Depo Provera


Loss of Bone Mineral Density

Use of Depo-Provera CI reduces serum estrogen levels and is associated with significant loss of bone mineral density (BMD). This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. It is unknown if use of Depo-Provera CI by younger women will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.
After discontinuing Depo-Provera CI in adolescents, mean BMD loss at total hip and femoral neck did not fully recover by 60 months (240 weeks) post-treatment [see Clinical Studies]. Similarly, in adults, there was only partial recovery of mean BMD at total hip, femoral neck and lumbar spine towards baseline by 24 months post-treatment. [See Clinical Studies]
Depo-Provera CI should not be used as a long-term birth control method (i.e., longer than 2 years) unless other birth control methods are considered inadequate. BMD should be evaluated when a woman needs to continue to use Depo-Provera CI long-term. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity.
Other birth control methods should be considered in the risk/benefit analysis for the use of Depo-Provera CI in women with osteoporosis risk factors. Depo-Provera CI can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). Although there are no studies addressing whether calcium and Vitamin D may lessen BMD loss in women using Depo-Provera CI, all patients should have adequate calcium and Vitamin D intake.

Thromboembolic Disorders

There have been reports of serious thrombotic events in women using Depo-Provera CI (150 mg). However, Depo-Provera CI has not been causally associated with the induction of thrombotic or thromboembolic disorders. Any patient who develops thrombosis while undergoing therapy with Depo-Provera CI should discontinue treatment unless she has no other acceptable options for birth control.
Do not readminister Depo-Provera CI pending examination if there is a sudden partial or complete loss of vision or if there is a sudden onset of proptosis, diplopia, or migraine. Do not readminister if examination reveals papilledema or retinal vascular lesions.

Cancer Risks

Breast Cancer
Women who currently have or have had breast cancer should not use hormone contraceptives, including Depo-Provera CI, because breast cancer may be hormonally sensitive. Women with a strong family history of breast cancer or who have breast nodules should be monitored with particular care.
A pooled analysis from two case-control studies, the World Health Organization Study and the New Zealand Study, reported the relative risk (RR) of breast cancer for women who had ever used Depo-Provera CI as 1.1 (95% confidence interval [CI] 0.97 to 1.4). Overall, there was no increase in risk with increasing duration of use of Depo-Provera CI. The RR of breast cancer for women of all ages who had initiated use of Depo-Provera CI within the previous 5 years was estimated to be 2.0 (95% CI 1.5 to 2.8).
The World Health Organization Study, a component of the pooled analysis described above, showed an increased RR of 2.19 (95% CI 1.23 to 3.89) of breast cancer associated with use of Depo-Provera CI in women whose first exposure to drug was within the previous 4 years and who were under 35 years of age. However, the overall RR for ever-users of Depo-Provera CI was 1.2 (95% CI 0.96 to 1.52).
The National Cancer Institute reports an average annual incidence rate for breast cancer for US women, all races, age 15 to 34 years of 8.7 per 100,000. A RR of 2.19, thus, increases the possible risk from 8.7 to 19.0 cases per 100,000 women.
Cervical Cancer
A statistically nonsignificant increase in RR estimates of invasive squamous-cell cervical cancer has been associated with the use of Depo-Provera CI in women who were first exposed before the age of 35 years (RR 1.22 to 1.28 and 95% CI 0.93 to 1.70). The overall, nonsignificant relative rate of invasive squamous-cell cervical cancer in women who ever used DEPO-PROVERA CI was estimated to be 1.11 (95% CI 0.96 to 1.29). No trends in risk with duration of use or times since initial or most recent exposure were observed.
Other Cancers
Long-term case-controlled surveillance of users of Depo-Provera CI found no overall increased risk of ovarian or liver cancer.

Ectopic Pregnancy

Be alert to the possibility of an ectopic pregnancy among women using Depo-Provera CI who become pregnant or complain of severe abdominal pain.

Anaphylaxis and Anaphylactoid Reaction

Anaphylaxis and anaphylactoid reaction have been reported with the use of Depo-Provera CI. Institute emergency medical treatment if an anaphylactic reaction occurs.

Liver Function

Discontinue Depo-Provera CI use if jaundice or acute or chronic disturbances of liver function develop. Do not resume use until markers of liver function return to normal and Depo-Provera CI causation has been excluded.


There have been a few reported cases of convulsions in patients who were treated with Depo-Provera CI. Association with drug use or pre-existing conditions is not clear.


Monitor patients who have a history of depression and do not readminister Depo-Provera CI if depression recurs.

Bleeding Irregularities

Most women using Depo-Provera CI experience disruption of menstrual bleeding patterns. Altered menstrual bleeding patterns include amenorrhea, irregular or unpredictable bleeding or spotting, prolonged spotting or bleeding, and heavy bleeding. Rule out the possibility of organic pathology if abnormal bleeding persists or is severe, and institute appropriate treatment.
As women continue using Depo-Provera CI, fewer experience irregular bleeding and more experience amenorrhea. In clinical studies of Depo-Provera CI, by month 12 amenorrhea was reported by 55% of women, and by month 24, amenorrhea was reported by 68% of women using Depo-Provera CI.

Weight Gain

Women tend to gain weight while on therapy with Depo-Provera CI. From an initial average body weight of 136 Ib, women who completed 1 year of therapy with Depo-Provera CI gained an average of 5.4 Ib. Women who completed 2 years of therapy gained an average of 8.1 Ib. Women who completed 4 years gained an average of 13.8 Ib. Women who completed 6 years gained an average of 16.5 Ib. Two percent of women withdrew from a large-scale clinical trial because of excessive weight gain.

Carbohydrate Metabolism

A decrease in glucose tolerance has been observed in some patients on Depo-Provera CI treatment. Monitor diabetic patients carefully while receiving Depo-Provera CI.


Detectable amounts of drug have been identified in the milk of mothers receiving Depo-Provera CI. In nursing mothers treated with Depo-Provera CI, milk composition, quality, and amount are not adversely affected. Neonates and infants exposed to medroxyprogesterone from breast milk have been studied for developmental and behavioral effects through puberty. No adverse effects have been noted.

Fluid Retention

Because progestational drugs including Depo-Provera CI may cause some degree of fluid retention, monitor patients with conditions that might be influenced by this condition, such as epilepsy, migraine, asthma, and cardiac or renal dysfunction.

Return of Fertility

Return to ovulation and fertility is likely to be delayed after stopping Depo-Provera CI. In a large US study of women who discontinued use of Depo-Provera CI to become pregnant, data are available for 61% of them. Of the 188 women who discontinued the study to become pregnant, 114 became pregnant. Based on Life-Table analysis of these data, it is expected that 68% of women who do become pregnant may conceive within 12 months, 83% may conceive within 15 months, and 93% may conceive within 18 months from the last injection. The median time to conception for those who do conceive is 10 months following the last injection with a range of 4 to 31 months, and is unrelated to the duration of use. No data are available for 39% of the patients who discontinued Depo-Provera CI to become pregnant and who were lost to follow-up or changed their mind.

Sexually Transmitted Diseases

Patients should be counseled that Depo-Provera CI does not protect against HIV infection (AIDS) and other sexually transmitted diseases.


Although Depo-Provera CI should not be used during pregnancy, there appears to be little or no increased risk of birth defects in women who have inadvertently been exposed to medroxyprogesterone acetate injections in early pregnancy. Neonates exposed to medroxyprogesterone acetate in-utero and followed to adolescence showed no evidence of any adverse effects on their health including their physical, intellectual, sexual or social development.


A woman who is taking hormonal contraceptive should have a yearly visit with her healthcare provider for a blood pressure check and for other indicated healthcare.

Interference with Laboratory Tests

The use of Depo-Provera CI may change the results of some laboratory tests, such as coagulation factors, lipids, glucose tolerance, and binding proteins. [See DRUG INTERACTIONS].

Patient Counseling Information

See FDA Approved Patient Labeling.
  • Advise patients at the beginning of treatment that their menstrual cycle may be disrupted and that irregular and unpredictable bleeding or spotting results, and that this usually decreases to the point of amenorrhea as treatment with Depo-Provera CI continues, without other therapy being required.
  • Counsel patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
  • Counsel patients on WARNINGS AND PRECAUTIONS associated with use of Depo-Provera CI.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment of Fertility


Use In Specific Populations


Depo-Provera CI should not be administered during pregnancy. See WARNINGS AND PRECAUTIONS.

Nursing Mothers

Detectable amounts of drug have been identified in the milk of mothers receiving Depo-Provera CI. [See WARNINGS AND PRECAUTIONS]

Pediatric Use

Depo-Provera CI is not indicated before menarche. Use of Depo-Provera CI is associated with significant loss of BMD. This loss of BMD is of particular concern during adolescence and early adulthood, a critical period of bone accretion. In adolescents, interpretation of BMD results should take into account patient age and skeletal maturity. It is unknown if use of Depo-Provera CI by younger women will reduce peak bone mass and increase the risk of osteoporotic fractures in later life. Other than concerns about loss of BMD, the safety and effectiveness are expected to be the same for postmenarchal adolescents and adult women.

Geriatric Use

This product has not been studied in post-menopausal women and is not indicated in this population.

Renal Impairment

The effect of renal impairment on Depo-Provera CI pharmacokinetics has not been studied.

Hepatic Impairment

The effect of hepatic impairment on Depo-Provera CI pharmacokinetics has not been studied. Depo-Provera CI should not be used by women with significant liver disease and should be discontinued if jaundice or disturbances of liver function occur. [See CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS]

For more info you may refer to the below website


(medroxyprogesterone acetate) Injectable Suspension, for Intramuscular Use
Women who use Depo-Provera Contraceptive Injection may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.
It is unknown if use of Depo-Provera Contraceptive Injection during adolescence or early adulthood, a critical period of bone accretion, will reduce peak bone mass and increase the risk for osteoporotic fracture in later life.
Depo-Provera Contraceptive Injection should not be used as a long-term birth control method (i.e., longer than 2 years) unless other birth control methods are considered inadequate. (See WARNINGS AND PRECAUTIONS

What are the possible side effects of medroxyprogesterone (Depo-Provera, Depo-Provera Contraceptive, Depo-SubQ Provera 104)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
  • sudden numbness or weakness, especially on one side of the body;
  • sudden headache, confusion, problems with vision, speech, or balance;
  • fever;
  • jaundice (yellowing of...
Read All Potential Side Effects and See Pictures of Depo Provera »


The following important adverse reactions observed with the use of Depo-Provera CI are discussed in greater detail in the WARNINGS AND PRECAUTIONSsection:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In the two pivotal clinical trials with Depo-Provera CI, over 3,900 women, who were treated for up to 7 years, reported the following adverse reactions, which may or may not be related to the use of Depo-Provera CI. The population studied ranges in age from 15 to 51 years, of which 46% were White, 50% Non-White, and 4.9% Unknown race. The patients received 150 mg Depo-Provera CI every 3-months (90 days). The median study duration was 13 months with a range of 1-84 months. Fifty eight percent of patients remained in the study after 13 months and 34% after 24 months.
Table 1: Adverse Reactions that Were Reported by More than 5% of Subjects
Body System*Adverse Reactions (Incidence (%))
Body as a WholeHeadache (16.5%)
Abdominal pain/discomfort (11 .2%)
Metabolic/NutritionalIncreased weight > 10 Ibs at 24 months (37.7%)
NervousNervousness (10.8%)
Dizziness (5.6%)
Libido decreased (5.5%)
UrogenitalMenstrual irregularities: bleeding (57.3% at 12 months, 32.1% at 24 months)
amenorrhea (55% at 12 months, 68% at 24 months)
* Body System represented from COSTART medical dictionary.

Table 2: Adverse Reactions that Were Reported by between 1 and 5% of Subjects
Body System*Adverse Reactions (Incidence (%)
Body as a WholeAsthenia/fatigue (4.2%)
Backache (2.2%)
Dysmenorrhea (1 .7%)
Hot flashes (1.0%)
DigestiveNausea (3.3%)
Bloating (2.3%)
Metabolic/NutritionalEdema (2.2%)
MusculoskeletalLeg cramps (3.7%)
NervousDepression (1 .5%)
Insomnia (1.0%)
Skin and AppendagesAcne (1.2%), No hair growth/alopecia (1.1%)
Rash (1.1%)
UrogenitalLeukorrhea (2.9%)
Breast pain (2.8%)
Vaginitis (1.2%)
Body System represented from COSTART medical dictionary.

Adverse reactions leading to study discontinuation in ≥ 2% of subjects: bleeding (8.2%), amenorrhea (2.1%), weight gain (2.0%)

Post-marketing Experience

The following adverse reactions have been identified during post approval use of Depo-Provera CI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
There have been cases of osteoporosis including osteoporotic fractures reported post-marketing in patients taking Depo-Provera CI.
Table 3: Adverse Reactions Reported during Post-Marketing Experience
Body SystemAdverse Reactions
Body as a WholeChest pain, Allergic reactions, Fever, Pain at injection site, Chills, Axillary swelling
CardiovascularSyncope, Tachycardia, Thrombophlebitis, Deep vein thrombosis, Pulmonary embolus, Varicose veins
DigestiveChanges in appetite, Gastrointestinal disturbances, Jaundice, Excessive thirst, Rectal bleeding
Hematologic and LymphaticAnemia, Blood dyscrasia
NervousParalysis, Facial palsy, Paresthesia, Drowsiness
RespiratoryDyspnea and asthma, Hoarseness
Skin and AppendagesHirsutism, Excessive sweating and body odor, Dry skin, Scleroderma
UrogenitalCervical cancer, Breast cancer, Lack of return to fertility, Unexpected pregnancy, Prevention of lactation, Changes in breast size, Breast lumps or nipple bleeding, Galactorrhea, Melasma, Chloasma, Increased libido, Uterine hyperplasia, Genitourinary infections, Vaginal cysts, Dyspareunia
* Body System represented from COSTART medical dictionary.

Friday, April 29, 2011

Birth control patch linked to higher fatality rate

Let's take a stand together!!!

Another day another dollar!!! In my effort to educate the public on contraceptive deaths. Please take a moment today and let your voice be heard. Please go to and sign the petition to ban certain types of contraceptives from the market. Thank you!!!

If there is anyone out there with a story like my sisters please feel free to contact me. I would like to post your story and some pictures of the loved one you lost on my blog. This is bigger than my sister. Please let your voice be heard. Love you all and God bless you!!!

Thursday, April 28, 2011

Cerebral venous sinus thrombosis (CVST)

The above diagnosis is what ultimately lead to my sister death. For now I will only put up a brief summary of what that is. If you would like to to continue reading about this in greater detail please feel free to go to the website I am providing.

Cerebral venous sinus thrombosis (CVST) is a rare form of stroke that results from thrombosis (a blood clot) of the dural venous sinuses, which drain blood from the brain. Symptoms may include headache, abnormal vision, any of the symptoms of stroke such as weakness of the face and limbs on one side of the body, and seizures. The diagnosis is usually by computed tomography (CT/CAT scan) or magnetic resonance imaging (MRI) employing radiocontrast to demonstrate obstruction of the venous sinuses by thrombus.[1]
Treatment is with anticoagulants (medication that suppresses blood clotting), and rarely thrombolysis (enzymatic destruction of the blood clot). Given that there is usually an underlying cause for the disease, tests may be performed to look for these. The disease may be complicated by raised intracranial pressure, which may warrant surgical intervention such as the placement of a shunt.[1] There are several other terms for the condition, such as cerebral venous and sinus thrombosis, (superior) sagittal sinus thrombosis, dural sinus thrombosis and intracranial venous thrombosis as well as the older term cerebral thrombophlebitis.

Signs and symptoms
Nine in ten people with sinus thrombosis have a headache; this tends to worsen over the period of several days, but may also develop suddenly (thunderclap headache).[1] The headache may be the only symptom of cerebral venous sinus thrombosis.[2] Many patients have symptoms of stroke: inability to move one or more limbs, weakness on one side of the face or difficulty speaking. This does not necessarily affect one side of the body as in the more common "arterial" stroke.[1]
40% of all patients have seizures, although it is more common still in women who develop sinus thrombosis peripartum (in the period before and after giving birth).[3] These are mostly seizures affecting only one part of the body and unilateral (occurring on one side), but occasionally the seizures are generalised and rarely they lead to status epilepticus (persistent or recurrent seizure activity for a long period of time).[1]
In the elderly, many of the aforementioned symptoms may not occur. Common symptoms in the elderly with this condition are otherwise unexplained changes in mental status and a depressed level of consciousness.[4]
The intracranial pressure (pressure around the brain) may rise, causing papilledema (swelling of the optic disc) which may be experienced as visual obscurations. In severely raised intracranial pressure, the level of consciousness is decreased, the blood pressure rises, the heart rate falls and the patient assumes an abnormal posture.[1]

[edit] Causes

Cerebral venous sinus thrombosis is more common in particular situations. 85% of patients have at least one of these risk factors:[1]

Wednesday, April 27, 2011

This is the story of my sister Julie Ann Woodby

On March 3rd 2008 I recieve a phone call from my Dad telling me that my 29 year old sister was admitted to the hosiptal after suffering a mild stroke. The Doctor's found a small bleed on the back of her brain. I quickly hung up with my Dad and proceeded to call my sister to find out in detail what had happened. I immediatly called my sister and began asking all the question a normal older sister would ask. I asked her if she fell, or if she was in an accident. Of  course the answers to the questions were no. She did say that she had a bad headache for about two to three days prior. So I just told her how much I loved her and that if she needed me I would fly out immediately. ( I live close to 2000 miles away). Around forty minutes after speaking to my sister I recieved another call from my Dad saying that my sister was gravely ill and that I needed to come out to Tennessee immediately. My sister had another stroke that cause a seizure and caused her to go into a coma. My heart dropped out of my mouth. To hear that your younger sister was gravely ill and would probably not make it was the worse news I have EVER heard in my life.

I flew out to TN the next morning. It happened to be the longest flight I have ever taken in my life. How could a healthy 29 year old women be gravely ill? Why was this happening to her? What can I do to help her?  I pondered all this on that long flight. Finally after enduring hours of pure torture I finally arrived in Knoxville, TN. When I got of the plane my Dad and cousin where there to greet. On the car ride to the hospital I learned that they had transported my sister to another hospital of a type of surgery that is preformed when there is extreme clotting in the veins on the top of the brain. (best way to describe the surgery is that it is simular to draino and pipes. Except they have to drill a hole just behind the ear and flush the veins with a blood thinner like substance.) When we finally go to the hospital that transported her to my sister was just being wheeled out of surgery. The doctors asked for my sisters family to come over to discuss how the procedure went. The Nuerologist stated that it was a risky procedure and her survival rate was only 30%. He also stated that the next 24 hours were very important. That if she was going to make it she would have to get past these next 24. My sister being the fighter that she always was did just that. As the hours passed she continued the biggest fight of her life.

While I waited that night I got together with the different doctors and asked all those questions that had been on my heart all day. How could a 29 year old woman just have a stroke and be fighting for her life? The answers I got left me utterly amazed. Specialist after specialist told me that the only thing that could have caused my sisters strokes, seizures and coma was the birth control she was on for a medical condition. My sister was not taking birth control to prevent unwanted pregnancy. She was on it for a non Llife threatening medical condition. Shortly after hearing this from the doctors I went back to sit with my sister. Just as I sat down my sisters heart stop and I was rush out of the ICU room where she had been since she had arrived.
My brother in law gave the go to restart my sisters heart and the doctors were successful. I could do nothing other than just sit there in complete shock. My baby sister was not going to make it. Now we had to make the decision would we have her heart restarted again if it stopped?? My brother in law, my dad and I made the decision to let her go if that happened once again.

Around 10-15 minutes later the doctors came in to see us to advise us that they were going to do an apnea test in the morning. This would determine if my sister had any brain function left or if she was as doctors say brain dead. It seemed like that night wouldn't end. I prayed to God to give us that miracle that we so needed.

Early morning came and before we knew it this young gentleman came into to do the Apnea test. There were only 2 family members allowed in the room. So we decided as a family that it would be my brother in law and I that would be in there for the test. I do have to say that was the longest 10 minute test of my life. They turned off life support then inserted a tube into her lungs that gave her oxygen to see if she would take a breath unassisted. I prayed and hoped that she would but as the 10 minutes came and went it was evident that my sister was brain dead. Just shortly after the test the doctors declared my sister brain dead and now we needed to make decisions. My Baby sister was gone and there was nothing anyone could do about that.

The doctors informed us that my sister was in such good health that they wanted us to consider donating her organs. We all agreed that we should and out of our sorrow another family's prayers were answered.

It has been 3 long years since my sisters death and all that goes through my brain every single day of my life is how can I sit back and allow other women to die due to birth contol. I have over the past 3 years talked to senators, wrote to the FDA but no one will listen to me so that is how this blogg came about.
Over the next couple of day/weeks I will go into detail about the types of birth control and their side affects. I will also tell you about that ingredient that tripples your risks for heart attacks, strokes and seizure. I refuse to allow another family to endure the pain that my family and I have went through. If you have a simular story or know of anyone willing to help me please have them contact me. Please help me on my quest to educated women on this subject. I love all of you!!!
God Bless!!!!

Insignificant number of deaths!!! Hello!!!

Hello All!!

I spent the night last night tossing and turning with the above statement. You know growing up in the United States as a child it is pounded in your head that you can make a change. You have the ability to change laws make a difference and impact others with your voice. To tell you the truth in all reality that is not true. I have been working on this matter for 3 years and so far nothing. In my mission to get this educational program out I have talked to members of the FDA who will remain nameless. They said to me and I quote "the number of women dying is an insignificant number compared to the amount of meds prescribed." Hello!!!! What is wrong with this picture. I am sorry in my eyes one life is absolutely precious to disqualify that is so wrong. So what that tells me is that my Sister mean nothing to the people that be. (we are all just another number) That goes against everything and anything that we as American citizens are taught here in the U.S. I refuse to stay silent on behalf of all those who have died in vein. You know doctors, pharmacuetical companies and our government are all making money off of this issue. So why would they want to help me. Why would they want to see change?? Please help me get the word out. Education is the key..

Tuesday, April 26, 2011

Contraceptives that are higher risk.

Third generation oral contraceptives containing desogestrel tend to doubled the risk of venous thrombosis (30 cases for every 100,000 users per year of third generation oral contraceptives compared to 15 cases for every 100,000 users of second generation oral contraceptives) and lack of evidence of clinical benefit as compared to the second generation oral contraceptives. The third generation oral contraceptives containing desogestrel are:
  • Desogestrel and Ethinyl Estradiol (Duramed/Barr and Watson Pharmaceuticals)
  • Desogen (Organon)
  • Mircette (Duramed/Barr)
  • Velivet (Duramed)
  • Apri-28 (Duramed/Barr)
  • Kariva (Duramed/Barr)
  • Ortho-Cept (Ortho-McNeil)
  • Reclipsen (Watson)
  • Cyclessa (Organon)
These are just a few of the ones on the market. Please note that if you or anyone out there is taking a pill that contains this element to please consult with your doctor first dont just stop them. I am not knocking birth control but I am saying that as females we need to know what it is we are putting in our bodies and how they will affect us. If you research more on this you will find that the contraceptives that came out back in the 60's seem to be somewhat safer than the altered ones created today. There are more details on this subject at www. . This particular site is trying to ban these drugs from the market but you and I all know that this is not reality. So I am  approaching this on a different level which is that of education.
We as a people can get together to make an impact if we work together and educated ourselves. So again I ask you for your help with this matter. I love you and God Bless  You!!!